Trial · NCT05692154
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3) | Arm A (Active-active) | 16.96 | Standard Deviation 9.090 | Sum of scores*hours | |
| Area Under Curve (AUC) of the Total Nasal Symptoms Score (TNSS-3) | Arm B (Placebo-active) | 21.42 | Standard Deviation 10.431 | Sum of scores*hours | |
| AUC of Total Ocular Symptoms Score (TOSS) (H0-H6 at Day 4) | Arm A (Active-active) | 11.74 | Standard Deviation 10.451 | Sum of scores*hours | |
| AUC of Total Ocular Symptoms Score (TOSS) (H0-H6 at Day 4) | Arm B (Placebo-active) | 16.21 | Standard Deviation 11.253 | Sum of scores*hours | |
| AUC of Total Nasal Symptoms Score (TNSS-3) (H0-H12 at Day 4) | Arm A (Active-active) | 23.66 | Standard Deviation 14.049 | Sum of scores*hours | |
| AUC of Total Nasal Symptoms Score (TNSS-3) (H0-H12 at Day 4) | Arm B (Placebo-active) | 31.01 | Standard Deviation 18.555 | Sum of scores*hours | |
| AUC of Total Ocular Symptoms Score (TOSS) (H0-H12 at Day 4) | Arm A (Active-active) | 14.74 | Standard Deviation 14.432 | Sum of scores*hours | |
| AUC of Total Ocular Symptoms Score (TOSS) (H0-H12 at Day 4) | Arm B (Placebo-active) | 21.67 | Standard Deviation 17.154 | Sum of scores*hours | |
| AUC of Total Nasal Symptoms Score (TNSS-3) (Day 1 to Day 4) | Arm A (Active-active) | 56.34 | Standard Deviation 55.697 | Sum of scores*hours | |
| AUC of Total Nasal Symptoms Score (TNSS-3) (Day 1 to Day 4) | Arm B (Placebo-active) | 65.48 | Standard Deviation 76.454 | Sum of scores*hours | |
| AUC of Total Ocular Symptoms Score (TOSS) (Day 1 to Day 4) | Arm A (Active-active) | 39.51 | Standard Deviation 55.416 | Sum of scores*hours | |
| AUC of Total Ocular Symptoms Score (TOSS) (Day 1 to Day 4) | Arm B (Placebo-active) | 47.21 | Standard Deviation 69.443 | Sum of scores*hours | |
| Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) | Arm A (Active-active) | 19.1 | percentage of participants | ||
| Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) | Arm B (Placebo-active) | 12.8 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05692154/results